MTOR and myeloproliferative disorder: In fact, the abnormal activation of mTOR in cancer cells and its role in many critical cellular processes, together with the availability of a growing number of molecules entering the clinical scenario, makes it an attractive target for therapy in neoplasia where involvement of the mTOR pathway contributes to disease pathogenesis; activation of this pathway has been demonstrated in MPN cells [29], [30], JAK2V617F-expressing mice [19], [38] and primary samples [41], [43].